Could a new staging system better predict esophageal cancer outcomes?

NCT ID NCT07488624

First seen Jun 26, 2026 · Last updated Aug 14, 2026 · Updated 3 times

Summary

This study analyzed data from 414 esophageal cancer patients who received chemoimmunotherapy before surgery. Researchers developed a new 'bio-anatomical' staging system that combines tumor characteristics and immune response to better predict survival and guide post-surgery treatment decisions. The goal is to improve upon traditional staging methods for personalized care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to
If successful, this could lead to a more accurate tool for doctors to predict survival and choose the best follow-up treatment for esophageal cancer patients after chemoimmunotherapy and surgery.
What could go wrong
This is a retrospective observational study, not a clinical trial testing a new treatment. The model needs further validation in prospective studies before it can be used in practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESCC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Mianzhu People's Hospital (West China Mianzhu Hospital, Sichuan University)

    Mianzhu, Sichuan, 618200, China

  • Suining Central Hospital

    Suining, Sichuan, 629000, China

  • West China Hospital, Sichuan University

    Chengdu, Sichuan, 610041, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.